Related Experiment Video

Updated: Aug 16, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Use of insulin glargine in children under age 6 with type 1 diabetes

Brenner Dixon1, H Peter Chase, Jonathan Burdick

  • 1Department of Pediatrics, Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, CO, USA.

Pediatric Diabetes
|August 20, 2005
PubMed

Insights

Insulin glargine significantly reduced severe hypoglycemia (SH) in young children with type 1 diabetes (T1D), especially nighttime events. This study evaluated glargine

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Management

Background:

  • Children under 6 face the highest risk of severe hypoglycemia (SH) and associated brain damage.
  • Type 1 diabetes (T1D) management in this age group presents unique challenges.
  • Understanding the safety and efficacy of newer insulin analogs is crucial.

Purpose of the Study:

  • To evaluate the use of insulin glargine in children under age 6 with type 1 diabetes (T1D).
  • To assess the impact of insulin glargine on severe hypoglycemia events in this vulnerable population.

Main Methods:

  • Retrospective review of electronic medical records for patients under 6 years old on insulin glargine.
  • Comparison with age, sex, and duration-matched controls on neutral protamine Hagedorn (NPH) insulin.
  • Data collection included hypoglycemic events, HbA1c, BMI, insulin dose, and Quality of Life (QoL) surveys.

Main Results:

  • Insulin glargine use was associated with a significant decrease in severe hypoglycemia events (16 to 3).
  • Nighttime severe hypoglycemia events dramatically reduced from 12 to 1 in the glargine group.
  • No significant differences were observed in HbA1c, BMI, or QoL between glargine and NPH groups.

Conclusions:

  • Insulin glargine effectively reduced severe hypoglycemia, particularly nocturnal episodes, in young children with T1D.
  • Insulin glargine represents a valuable therapeutic option for managing T1D in pre-school-aged children.
  • Further research may explore long-term outcomes and optimal dosing strategies.
Abstract

More Related Videos

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...